Nurix Therapeutics (NRIX) Common Equity (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Common Equity for 8 consecutive years, with $402.6 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Common Equity fell 10.05% year-over-year to $402.6 million; the TTM figure through May 2026 stood at $402.6 million (down 10.05% YoY), while the FY2025 annual figure was $538.7 million, up 2.23% from the prior year.
• Common Equity eased to $402.6 million in Q2 2026 per NRIX's latest filing, from $480.9 million in the prior quarter.
• Across five years, Common Equity topped out at $538.7 million in Q4 2025 and bottomed at $168.7 million in Q1 2024.
• Historically, Common Equity has averaged $353.0 million across 5 years, with a median of $356.6 million in 2022.
• Annual changes were most pronounced in 2024 — Common Equity plunged 38.42% — and 2025, when it soared 184.99%.
• Nurix Therapeutics' Common Equity stood at $303.7 million in 2022, then slumped by 33.98% to $200.5 million in 2023, then surged by 162.85% to $527.0 million in 2024, then climbed by 2.23% to $538.7 million in 2025, then fell by 25.27% to $402.6 million in 2026.
• Business Quant data shows NRIX's Common Equity at $402.6 million in Q2 2026, $480.9 million in Q1 2026, and $538.7 million in Q4 2025.